Open an account

Veraxa Biotech AG

VRXA · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed ·
Prev close $1.00

About VRXA

Veraxa Biotech AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Zurich, Zuerich. The company went IPO on 2026-06-11. Veraxa Biotech AG is a Switzerland-based Company that develops antibody-based therapeutics for the treatment of cancer. The firm focuses on advancing proprietary platform technologies designed to generate targeted oncology therapies with improved safety and efficacy profiles. Its approach originates from scientific discoveries at the European Molecular Biology Laboratory, supporting the development of next-generation antibody-based drug candidates. The firm aims to expand treatment options for solid tumors by enabling more precise targeting mechanisms and potentially broader therapeutic windows compared with conventional therapies, addressing unmet needs across oncology markets through platform-driven innovation.

Employees
0
Headquarters
Zurich, Zuerich
Listed
Jun 11, 2026
Sector
Health Care
Industry
Biotechnology

VRXA key statistics

Market cap
163.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
265.90K
Volume
126.63K
Open price
$1.09
High today
$1.09
Low today
$0.99
52 Week high
$27.36
52 Week low
$1.00

Veraxa Biotech AG (VRXA) at a glance

Veraxa Biotech AG (VRXA) last traded at $1.01, with a market cap of 163.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.99 and $1.09. The current price is 2.0% above the day's low and 7.3% below its high.

Volume so far is 126.63K shares, below the average of 265.90K shares a day.

Over the past year Veraxa Biotech AG has ranged from $1.00 to $27.36, and now sits 0% of the way up that range.

VRXA news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Veraxa Biotech Initiated Cell Line Development For Its Lead BiTAC T-cell Engager Program

  • Press releaseGlobe Newswire

    VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Crude Oil Down Over 3%; US Consumer Sentiment Rises In June

Similar companies

Companies in the same industry as Veraxa Biotech AG

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.